Semisynthetic analog of fumagillin that inhibits angiogenesis. Prepn: S. Kishimoto, T. Fujita, EP 359036; eidem, US 5166172 (1990, 1992 both to Takeda); S. Marui et al., Chem. Pharm. Bull. 40, 96 (1992). Antiangiogenic activity: M. Kusaka et al., Biochem. Biophys. Res. Commun. 174, 1070 (1991). HPLC determn in plasma: W. D. Figg et al., J. Chromatogr. B 652, 187 (1994). Review of pharmacology: V. Castronovo, D. Belotti, Eur. J. Cancer 32A, 2520-2527 (1996). Clinical evaluation in metastatic renal carcinoma: W. M. Stadler et al., J. Clin. Oncol. 17, 2541 (1999). Clinical pharmacokinetics in Kaposi's sarcoma: J. D. Moore et al., Cancer Chemother. Pharmacol. 46, 173 (2000).
This monograph has been retired and is no longer subject to revision or update.